Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly (LLY-2.55%) is working to capture as much of that market as it can, and it's probably going to succeed. Here's why. The juggernaut is picking up speed ...

Eli Lilly (LLY) is following the right approach for the obesity drugs business as it explores multiple ways to address the balance between demand and supply, according to Truist Securities. The ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor.Clinical trial results from competitors were largely underwhelming, including this week’s ...

Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030. Orforglipron lowered A1C by 1.3%–1.6% from baseline in Phase 3 ACHIEVE-1 trial. Historic Summer Setup: 3 "Power ...

Sales of diabetes-obesity drug Mounjaro could play a big role at Lilly in future years. Photo: Sandy Huffaker for The Washington Post/Getty Images Eli Lilly LLY 0.18 % increase; green up pointing ...

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050.

Eli Lilly. Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050. We got a glimpse ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.